SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/219567"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/219567" > MRI assessment of e...

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Ostergaard, M. (författare)
Jacobsson, Lennart T. H., 1954- (författare)
Göteborgs universitet, Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning, Gothenburg University, Institute of Medicine, Department of Rheumatology and Inflammation Research
Schaufelberger, C., (författare)
Göteborgs universitet, Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning, Gothenburg University, Institute of Medicine, Department of Rheumatology and Inflammation Research
visa fler...
Hansen, M. S. (författare)
Bijlsma, J. W. J. (författare)
Dudek, A. (författare)
Rell-Bakalarska, M. (författare)
Staelens, F. (författare)
Haake, R. (författare)
Sundman-Engberg, B. (författare)
Bliddal, H. (författare)
visa färre...
Göteborgs universitet Sahlgrenska akademin. Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning. 
2015
Engelska.
Ingår i: Annals of the Rheumatic Diseases. - 0003-4967. ; 74:6, s. 1156-1163
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objectives To identify the first time point of an MRI-verified response to certolizumab pegol (CZP) therapy in patients with rheumatoid arthritis (RA). Methods Forty-one patients with active RA despite disease-modifying antirheumatic drug therapy were randomised 2:1 to CZP (CZP loading dose 400mg every 2weeksat weeks 0-4; CZP 200mg every 2weeksat weeks 6-16) or placeboCZP (placebo at weeks 0-2; CZP loading dose at weeks 2-6; CZP 200mg every 2weeks at weeks 8-16). Contrast-enhanced MRI of one hand and wrist was acquired at baseline (week 0) and weeks 1, 2, 4, 8 and 16. All six time points were read simultaneously, blinded to time, using the Outcome Measures in Rheumatology Clinical Trials RA MRI scoring system. Primary outcome was change in synovitis score in the CZP group; secondary outcomes were change in bone oedema (osteitis) and erosion scores and clinical outcome measures. Results Forty patients were treated (27 CZP, 13 placeboCZP), and 36 (24 CZP, 12 placeboCZP) completed week 16. In the CZP group, there were significant reductions from baseline synovitis (Hodges-Lehmann estimate of median change, -1.5, p=0.049) and osteitis scores (-2.5, p=0.031) at week 16. Numerical, but statistically insignificant, MRI inflammation reductions were observed at weeks 1-2 in the CZP group. No significant change was seen in bone erosion score. Improvements across all clinical outcomes were seen in the CZP group. Conclusions CZP reduced MRI synovitis and osteitis scores at week 16, despite small sample size and the technical challenge of reading six time points simultaneously. This study provides essential information on optimal MRI timing for subsequent trials.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

Rheumatoid Arthritis
Magnetic Resonance Imaging
Anti-TNF
Inflammation
Synovitis
BONE-MARROW EDEMA
SUBSEQUENT RADIOGRAPHIC PROGRESSION
SPACE NARROWING
SCORE
DISEASE-ACTIVITY
INFLAMMATORY ACTIVITY
STRUCTURAL DAMAGE
RELIABILITY
SYNOVITIS
RESPONSIVENESS
METHOTREXATE
Rheumatology

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy